CGEMCullinan Therapeutics, Inc.

CGEM Stock Price, Valuation & Chart | Cullinan Therapeutics, Inc.

Compare

$21.790-0.28 (-1.27%)

At close · 01 Sept 2026, 08:00 pm

Sector: Healthcare Industry: Medical - Pharmaceuticals CGEM intrinsic value CGEM calculated fair value vs price

Overview Financials Dividends Ratios

CGEM Historical price chart

CGEM Key Stats

Fair Value

Disclaimer

Disclaimer: This fair value estimate is for informational purposes only and should not be considered as investment advice. Fair value calculations are based on DCF (Discounted Cash Flow), P/E Multiple, and P/S Multiple models and assumptions that may not reflect actual market conditions. Always conduct your own research and consult with a financial advisor before making investment decisions.

Unlock

Market Capitalization1.34B

PE Ratio-7.03

EPS-3.1

Trading Volume546.14K

Today's High/Low22.07/21.55

Dividend Yield0.00

52 Week High/Low23.19/5.68

Shares Outstanding61.46M

CGEM Financial Statement

CGEM Analyst ratings

CGEM Analysis & performance metrics

CGEM Company profile

Cullinan Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the developing of oncology and immuno-oncology therapies. Its pipeline includes…

Cullinan Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the developing of oncology and immuno-oncology therapies. Its pipeline includes CLN-978, CLN-619, Zipalertinib CLN-081/TAS6417, CLN-049, and CLN-617. The company was founded by Patrick A. Baeuerle on September 15, 2016 and is headquartered in Cambridge, MA.

CGEM Management team

Name

Position

Nadim AhmedCEO

President, Chief Executive Officer & Director

Jeffrey Jones M.B.A., M.D., M.P.H.

Chief Medical Officer

Kevin A. Johnston

Chief Technical Operations Officer

Steve Andre

Chief Human Resources Officer

Rose Weldon

Senior Vice President of Corporate Affairs

Patrick A. Baeuerle Ph.D.

Co-Founder, Chief Scientific Advisor & Chairman of Scientific Advisory Board

Jacquelyn L. Sumer J.D.

Chief Legal Officer, Chief Compliance Officer & Corporate Secretary

Corinne Savill Ph.D.

Chief Business Officer

Name

Position

Nadim AhmedCEO

President, Chief Executive Officer & Director

Jeffrey Jones M.B.A., M.D., M.P.H.

Chief Medical Officer

Kevin A. Johnston

Chief Technical Operations Officer

Steve Andre

Chief Human Resources Officer

Rose Weldon

Senior Vice President of Corporate Affairs

Patrick A. Baeuerle Ph.D.

Co-Founder, Chief Scientific Advisor & Chairman of Scientific Advisory Board

Jacquelyn L. Sumer J.D.

Chief Legal Officer, Chief Compliance Officer & Corporate Secretary

Corinne Savill Ph.D.

Chief Business Officer

Management Team

Nadim AhmedCEO

President, Chief Executive Officer & Director

Jeffrey Jones M.B.A., M.D., M.P.H.

Chief Medical Officer

Kevin A. Johnston

Chief Technical Operations Officer

Steve Andre

Chief Human Resources Officer

Rose Weldon

Senior Vice President of Corporate Affairs

Patrick A. Baeuerle Ph.D.

Co-Founder, Chief Scientific Advisor & Chairman of Scientific Advisory Board

Jacquelyn L. Sumer J.D.

Chief Legal Officer, Chief Compliance Officer & Corporate Secretary

Corinne Savill Ph.D.

Chief Business Officer

Management

Nadim AhmedCEO

President, Chief Executive Officer & Director

Jeffrey Jones M.B.A., M.D., M.P.H.

Chief Medical Officer

Kevin A. Johnston

Chief Technical Operations Officer

Steve Andre

Chief Human Resources Officer

Rose Weldon

Senior Vice President of Corporate Affairs

Patrick A. Baeuerle Ph.D.

Co-Founder, Chief Scientific Advisor & Chairman of Scientific Advisory Board

Jacquelyn L. Sumer J.D.

Chief Legal Officer, Chief Compliance Officer & Corporate Secretary

Corinne Savill Ph.D.

Chief Business Officer

Total 8 executives

CGEM Frequently asked questions

What is Cullinan Therapeutics, Inc. (CGEM) Stock Price?

Current stock price of Cullinan Therapeutics, Inc. (CGEM) stock is $21.790. The stock price is -1.27% lower in the session. The intraday range can be seen from this page. Volume of Cullinan Therapeutics, Inc. (CGEM) stock is 546.14K.

Last updated at 01 Sept 2026, 08:00 pm.

Why is the Cullinan Therapeutics, Inc. (CGEM) stock price going up or down today?

The stock price of Cullinan Therapeutics, Inc. (CGEM) can change with earnings, company news, and overall market sentiment. Cullinan Therapeutics, Inc. operates in the Healthcare / Medical - Pharmaceuticals market, so sector-wide moves can also affect the share price. Use the live price, percentage change, and volume on this page to judge whether a move looks meaningful.

Is the Cullinan Therapeutics, Inc. stock expensive at its current price?

Whether Cullinan Therapeutics, Inc. looks expensive depends on valuation metrics versus its growth outlook. The P/E ratio shown for CGEM on this page is -7.03. EPS on this page is -3.10. Compare those figures with peers and growth expectations before deciding if the current Cullinan Therapeutics, Inc. price is justified.

How has the stock price of Cullinan Therapeutics, Inc. (CGEM) performed historically?

Historical performance for Cullinan Therapeutics, Inc. (CGEM) is shown on the price chart on this page. Review multi-period moves alongside volume to see how CGEM reacted to past earnings and market events.

Should I buy Cullinan Therapeutics, Inc. (CGEM) stock, at this price?

Buying Cullinan Therapeutics, Inc. (CGEM) depends on your risk tolerance, time horizon, and portfolio needs. As a Healthcare name, weigh the live quote, key stats, and valuation links on this page rather than a single price point.